Teva Sued by UCB Over Generic Copy of Epilepsy Drug

Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest generic-drug maker, was sued for patent infringement by a U.S. unit of UCB SA (UCB) in a bid to block plans to copy the epilepsy drug Vimpat.

UCB, based in Brussels, seeks unspecified damages from Petach Tikva, Israel-based Teva, according to a complaint filed today in federal court in Wilmington, Delaware.

Denise Bradley, a Teva spokeswoman, said in an e-mailed message that the company would have no comment on the lawsuit.

To see the patent, click: RE 38,551.

The case is UCB v. Teva, 13-cv-01148, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.